ReseaRch Notes
R eporting adverse drug events (ADEs) by health care providers (HCPs) is an important component of postmarketing drug surveillance. HCPs in the United States are encouraged to report serious ADEs that they encounter to the Food and Drug Administration (FDA) through MedWatch. The reporting of ADEs enhances the identification of signals and risks associated with the use of drugs. Increasing ADE reporting is associated with improved safe use of available drugs. Many drugs have been withdrawn from the market on the basis of spontaneous reports. A total of 22 drugs were withdrawn from the Spanish market in the 1990s, based primarily on case series or reports. 1 Between 1969 and 2002, more than 75 drugs/ drug products (∼1% of marketed drugs) were removed from the market for safety reasons in the United States. 2 Pharmacists are in a unique position to detect and report ADEs because of their specialized training in pharmaceuticals and widespread use of computers. 3 However, the potential contribution of pharmacists to drug safety through ADE reporting is hampered by underreporting, which is a major problem. 4 A very small proportion of serious ADEs (<1%) are reported to FDA. 5 Underreporting delays the identification of signals and drug risks and complicates the analysis of data. 6 HCPs in many countries face several obstacles when reporting ADEs to pharmacovigilance centers, including inadequate knowledge of ADEs and ADE reporting, concerns about malpractice litigation, lack of motivation, lack of time, high workload, lack of economic incentive, complacency, indifference, ignorance of ADE reporting requirements, and negative attitudes among others. [7] [8] [9] [10] [11] [12] [13] [14] In addition, perceived ease of use of an ADE reporting system was found to have an important effect on HCPs' intention to report. 15 This indicates that perceptions of ease or difficulty may be important antecedents for pharmacist ADE reporting. However, no known U.S. study has investigated the factors that make it easier or more difficult for pharmacists to report serious ADEs to FDA. objective In this pilot study, we sought to identify barriers to and facilitators of pharmacist reporting of serious ADEs to FDA.
Method
The study was approved by the University of Texas at Austin Institutional Review Board. Data were collected through focus groups based on the methods of Ajzen and Fishbein. 16 Two focus groups were held in Austin, TX, during which the researcher conducted audiotaped interviews with a convenience sample of practicing Texas pharmacists. All practicing pharmacists attending graduate school at the University of Texas at Austin were invited through e-mail to attend the first focus group. A total of six pharmacists volunteered to participate in the study and were provided lunch for participating.
A local community pharmacist association leadership helped to recruit seven members who participated in the second focus group in Austin, TX. All pharmacists on the mailing list of the association were informed of the focus group and invited to participate in the study by the association leadership. The focus group was held immediately after the monthly meeting in the same venue as the monthly association meeting. The second focus group participants, who were all community pharmacists, were given a $25 gift card for participating. All potential focus group participants were informed of the time, date, and location of the focus group through e-mail. All focus group participants signed an informed consent form. Each focus group had the minimum of six to eight volunteers recommended in the literature. 17, 18 The purpose, length, and rules of the focus group were explained to all focus group volunteers. Both focus groups were moderated by the first author (P.G.), who has training and experience in moderating focus groups. The moderator guided the discussion using the outline of open-ended questions contained in the focus group interview guide. The following open-ended questions, which were adapted from Montano and Kasprzyk, 19 were used in the focus groups: (1) What do you think would make it easier to report serious ADEs to the FDA? (2) What do you think would make it more difficult to report serious ADEs to the FDA?
During the focus groups, the moderator probed for details and asked follow-up questions to elicit more discussion. Each focus group lasted approximately 1 hour. A content analysis was performed on the basis of the written transcriptions of the focus groups. The data were coded in order to facilitate the search for patterns and themes within the data.
Results
A total of 13 Texas pharmacists participated in the two focus groups. Most participants were white (n = 8 [61.5%]), men (n = 7 [53.8%]), and community pharmacists (n = 9 [69.2%]) and had been practicing pharmacy for an mean (±SD) of 12.08 ± 13.97 years ( Table 1) .
The focus group participants cited many factors that they believed served as barriers to and facilitators of reporting serious ADEs to FDA (Table 2) . Pharmacists believed that not having the patient's complete medical history made reporting serious ADEs difficult (n = 12). Also, a majority of participants (n = 10) believed that lack of time contributed to difficulty in reporting serious ADEs (Table 2) .
Discussion
Strategies to promote ADE reporting among pharmacists can be more successful if they are tailored to pharmacists' needs/ beliefs. This pilot study identified the main factors that make reporting easier or more difficult for pharmacists. An understanding of these factors can help to stimulate ideas for solutions to ADE underreporting. The most cited impediment to ADE reporting was lack of access to complete patient medical history. Without patient medical histories, pharmacists may find it difficult to establish an association between a drug and the ADE. Having access to patients' medical history may enhance pharmacists' confidence in iatrogenic diagnosis and patient counseling 20 and thus foster reporting. However, pharmacists do not need to have all the details (e.g., complete patient history, demographic data) to report serious ADEs.
Similar to previous studies, pharmacists believed that lack of time (to file a report or look for ADEs) increased difficulty in reporting serious ADEs to FDA. 13, 14, 21 Pharmacists' working conditions and other workplace issues may make it difficult for them to devote time to reporting. These include increased workload, high turnover, too much time spent on insurancerelated problems, hectic pace of practice, and increased prescription volumes. 22, 23 An urgent need exists to address these organizational factors so that pharmacists can find more time to submit ADE reports.
Focus group participants had misconceptions regarding ADE reporting in general and MedWatch specifically and on what to report. Consistent with previous studies, a majority of pharmacists mentioned that improved awareness of ADE reporting made reporting easier. 24, 25 Education interventions have been found to be effective at increasing ADE reporting and improving the quality of reports. 21, [26] [27] [28] If pharmacists have better knowledge concerning ADE reporting, they will find it easier to report. Measures are needed to increase pharmacist awareness of ADE reporting.
Lack of employer support for pharmacist ADE reporting was also found to increase difficulty. Similarly, Green 29 reported that encouragement from managers and departments would improve reporting. However, as a result of commercial pressures in pharmacy practice and high prescription volumes, ADE reporting may not be prioritized by employers and managers. Employers and managers should be sensitized to the importance of pharmacovigilance and encouraged to support pharmacists in their quest to report serious ADEs.
More empirical research using larger samples should be conducted to confirm this study's findings. Future research should quantify the extent to which these factors (individually and collectively) influence pharmacist ADE reporting intentions and behaviors. Further, future studies should identify interventions to address the barriers and thereby improve ADE reporting by pharmacists.
Limitations
The following study limitations should be considered in interpreting the results. First, the study population consisted of pharmacists practicing in a single geographic location (Austin, TX) and may not be representative of all pharmacists in Texas or other states. Second, the sample size was small (n = 13), making it difficult to conduct subgroup analysis (e.g., community versus noncommunity pharmacists). Finally, not all pharmacists had an equal chance of participating in this study given that this was a convenient sample. The study findings offer an understanding of the factors that make it easier (facilitators) or more difficult (barriers) to report serious ADEs to FDA. Improved knowledge of ADEs and ADE reporting would facilitate reporting behaviors, while lack of time, lack of complete patient medical histories, and lack of compensation issues serve as important barriers to reporting. Based on these findings, public health officials, drug safety experts, and pharmacy educators can gain insight into areas that need to be targeted to improve ADE reporting by pharmacists. More empirical research should be conducted to confirm this study's findings.
